PWAM
ABUS icon

Private Wealth Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Private Wealth Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51
Closed -$245 – 928
2025
Q4 		$245 Hold
51
– – ﹤0.01% 965
2025
Q3 		$232 Hold
51
– – ﹤0.01% 961
2025
Q2 		$158 Hold
51
– – ﹤0.01% 1020
2025
Q1 		$178 Buy
+51
New +$170 ﹤0.01% 1101

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Private Wealth Asset Management's ABUS Position: Q1 2026 in Review

Private Wealth Asset Management sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 51 shares — an estimated $245 sold.

Private Wealth Asset Management first reported a position in ABUS in Q1 2025 and held it in 4 quarters. The position peaked at $245 in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Private Wealth Asset Management reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Private Wealth Asset Management sold 51 Arbutus Biopharma shares in Q1 2026, an estimated $245.
  • Private Wealth Asset Management first reported a position in Arbutus Biopharma in Q1 2025 and held it in 4 quarters.
  • Private Wealth Asset Management's Arbutus Biopharma position peaked at $245 in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Private Wealth Asset Management's 13F filing for Q1 2026, filed 6 May 2026.